Jefferies Global Healthcare Conference in London - NATERA INC
Financial Performance:
- Reported a record quarter with 42% year-over-year organic revenue growth.
- Achieved strong sequential growth in Average Selling Prices (ASPs) across the portfolio, particularly for Signatera.
- Updated full-year 2024 revenue guidance to north of $3 billion, reflecting current scale and market penetration.
- Maintained strong organic gross margin performance despite the introduction of new technologies.
- Current Signatera ASP stands at approximately $1,290, with a target of $1,450 by 2029.
Guidance and Future Outlook:
- Set a strategic long-term revenue target of $6 billion by 2029, aiming to double the roughly $3 billion revenue expected in 2026.
- Projected the 2029 revenue bridge will be achieved through modest growth in women's health and transplant segments, continued unit growth in Signatera, and ASP expansion to $1,450.
- Anticipated doubling of the addressable market by 2029-2030 driven by the readout of the FIND study (early colorectal cancer detection).
- New patient starts are trending upward, expected to contribute 10-15% of total quarterly Signatera clinical volumes.
- Full cost optimization for the new Signatera Genome backbone is expected within a few quarters.
Business Segments and Product Lines:
- Signatera (Oncology): Core growth driver with 9 MOLDx coverage applications currently in flight; recently secured Medicare coverage for liver cancer.
- Signatera Genome: Newer technology utilizing whole-genome sequencing and phased structural variants to improve sensitivity; currently higher COGS expected to normalize.
- Women's Health & Transplant: Expected to deliver modest, continued growth with no heroic assumptions required.
- Pharma Services: Significant acceleration in contracted value and strategic trials following positive INVIGOR trial results with Roche, which enabled a drug approval previously unattainable.
- FIND Study: Large prospective outcomes trial for early colorectal cancer detection scheduled for readout next year.
Market and Competitive Landscape:
- Total addressable market for Signatera is estimated at ~$20 billion annually, with current penetration around $1 billion.
- Early cancer detection market faces high barriers to entry (approx. $400-500M R&D investment) but offers a massive opportunity for a blood test alternative to colonoscopies.
- Identified two primary competitors in the early detection space; management asserts confidence in capturing a fair share due to commercial execution strength and payer willingness to reimburse for non-compliant patient populations.
- Potential inclusion in NCCN clinical practice guidelines for colorectal and breast cancer over the next three years.
Risks and Challenges:
- High upfront R&D investment required for early cancer detection program (FIND study) with delayed commercial returns.
- Execution challenges regarding compliance with Medicare Advantage payers and commercial insurance in biomarker states.
- Temporary increase in Cost of Goods Sold (COGS) for the Signatera Genome platform during the ramp-up phase.
- Reimbursement uncertainty for early cancer detection tests prior to major clinical readouts.
Management Commentary and Tone:
- Management tone is highly confident and optimistic regarding future growth and market opportunity.
- Described the CEO transition as "natural" and "friendly," emphasizing deep continuity with 16-year veteran Solomon Moskovich succeeding Steve.
- Management emphasized that the $6 billion target is "eminently achievable" without heroic assumptions, relying on consistent execution.
- Expressed strong conviction that the early cancer market math "pencils out" given positive payer feedback on colorectal cancer screening.
Analyst Questions and Answers:
- Revenue Bridge: Clarified that the $6B target relies on volume growth and ASP increases driven by MOLDx coverage decisions (valued at $200-$300 impact) and compliance improvements.
- Volume Composition: New patient starts account for 10-15% of quarterly volumes; existing patient retention and test frequency over a 5-year journey drive the majority of revenue.
- MOLDx Expansion: Seven new indications previously discussed ($250-300M opportunity) are distinct from the ASP bridge; revenue impact scales with volume as indications are approved.
- Genome Technology: Clarified that phased variants are primarily an algorithmic addition with minimal cost impact, while whole-genome sequencing increases COGS temporarily.
- Pharma Growth: Highlighted the shift from exploration to strategic partnership post-INVIGOR trial, significantly increasing total contracted value.
Other Key Points:
- CEO Transition: Steve (8 years CEO, 16 with company) stepping aside; Solomon Moskovich (sales rep history, co-inventor of Prospera, original Signatera GM) taking over.
- Leadership Stability: Broad management team has high tenure, with multiple board members and executives serving 10+ years, fostering a unified strategy.
- Clinical Utility: High retention rates and compliance driven by the clinical utility of guiding adjuvant treatment and monitoring recurrence.
- Market Potential: 40 million Americans require colorectal cancer screening but avoid current methods; a blood test could capture 13-14 million users annually.
- Company
- NATERA INC
- Keywords
- NATERA INC